A vaccine to protect children from RSV and hMPV infections
Official title: An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV
Funded at Florida State University · NIH-11091552 · Data updated 2026-11-12
This study is working on a new vaccine to help protect children from two common respiratory viruses, RSV and hMPV, by combining parts of both viruses to boost their immune response and keep them healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida State University NIH-funded |
| Lab location | 1 site (Tallahassee, United States) |
| Project start | June 6, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $688,268 |
| NIH project number | 5R01AI173416-04 |
| Project ID | NIH-11091552 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under the age of 11, particularly those at high risk for respiratory infections.
✕Less likely to help
Patients who are older than 11 years or those who have already been vaccinated against RSV or hMPV may not benefit from this research.
What this research studies
This research aims to develop a new vaccine that targets two common respiratory viruses, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), which significantly affect children. The approach involves creating a chimeric vaccine that combines key components from both viruses to stimulate a strong immune response. By focusing on the most effective parts of the viruses, the vaccine seeks to provide broad protection and reduce the risk of severe illness in young patients. The research includes testing the vaccine in animal models to assess its safety and effectiveness before considering human trials.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces hospitalizations and deaths caused by RSV and hMPV in children.
How similar studies have gone: Previous research has shown promise in developing vaccines targeting RSV, but this specific chimeric approach is relatively novel.
Where this research is happening
-
Florida State University
Tallahassee, United States Active
Researchers
- Principal investigator: Mousa, Jarrod — Florida State University
- Study coordinator: Mousa, Jarrod
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.